Relationship between FRAS1 protein and brain metastases of NSCLC / 中国病理生理杂志

[ ABSTRACT] AIM: To explore the relationship between FRAS 1 protein and brain metastases of non-small cell lung cancer (NSCLC).METHODS:The mRNA expression of FRAS1 in the brain metastatic tumor tissues and primary tumor tissues of NSCLC was detected by qPCR .The protein expression of FRAS 1 in the tumor tissues and normal tissues adjacent to tumor tissues of NSCLC was measured by SP method of immunohistochemistry .The protein expression of FRAS 1 in NSCLC primary tumor tissues with or without brain metastases was also determined .RESULTS:The mRNA expression of FRAS1 in the brain metastatic zone was nearly 10 times higher than that in the primary tumor tissues , and there was sig-nificant difference between the 2 groups (P<0.05).FRAS1 protein was expressed in the NSCLC primary tumor tissues , but was not found in the normal tissues adjacent to primary tumor tissues .The protein expression of FRAS 1 in the NSCLC with brain metastases was significantly higher than that without brain metastases ( P<0.01 ) .CONCLUSION: FRAS1 protein may be associated with the occurrence of NSCLC .The over-expression of FRAS1 protein may be related to brain metastases with NSCLC .

Regorafenib in the treatment of malignant tumor / 国际肿瘤学杂志

Regorafenib,an oral multi-kinase inhibitor,can inhabit a class of receptor tyrosine kinase,such as angiogenic,stromal,oncogenic and so on.Studies in vitro and clinical trials indicate that Regorafenib has significant antitumor activity.The results of clinical trials are encouraging for the treatment of Refractory solid tumors,especially for colorectal carcinoma.